Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer
Status:
Completed
Trial end date:
2019-02-12
Target enrollment:
Participant gender:
Summary
This study will assess the safety and efficacy of LGX818 when combined with cetuximab or
combined with cetuximab and BYL719 in patients with BRAF mutant metastatic colorectal cancer